The Onyx Biotec IPO is a book-built issue amounting to Rs 29.34 crores. The entire issue consists of a fresh issuance of 48.1 lakh shares.
The Onyx Biotec IPO will open for subscription on November 13, 2024, and will close on November 18, 2024. The allotment for the IPO is expected to be finalized on Tuesday, November 19, 2024. The IPO will be listed on NSE SME, with a tentative listing date set for Thursday, November 21, 2024.
The price band for Onyx Biotec IPO has been set at ₹58 to ₹61 per share. A minimum lot size of 2000 shares is required for an application. Retail investors are required to make a minimum investment of ₹122,000, while the minimum investment for HNIs is set at 2 lots (4,000 shares), amounting to ₹244,000.
Get the Onyx Biotec IPO DRHP for detailed information.
| IPO Date | November 13, 2024 to November 18, 2024 |
| Listing Date | November 21, 2024 |
| Face Value | ₹ 10 / Share |
| Price Band | ₹ 58 to ₹ 61 / Share |
| Lot Size | 2000 Shares |
| Total Issue Size | ₹29.34 Cr |
| Fresh Issue | ₹29.34 Cr |
| Offer for Sale | |
| Employee Discount | |
| Issue Type | Book Built Issue IPO |
| Listing At | NSE SME |
| Share holding pre issue | 13,322,200 |
| Share holding post issue | 18,132,200 |
| Market Maker portion | 244,000 shares |
Onyx Biotec Limited IPO opens on November 13, 2024, and closes on November 18, 2024.
| IPO Open Date | November 13, 2024 |
| IPO Close Date | November 18, 2024 |
| Basis of Allotment | November 19, 2024 |
| Initiation of Refunds | November 20, 2024 |
| Credit of Shares to Demat | November 20, 2024 |
| Listing Date | November 21, 2024 |
| Cut-off time for UPI mandate confirmation | November 18, 2024 |
A minimum of 2000 shares can be bid for by investors, and bids may be placed in multiples of this quantity. The minimum and maximum investments by retail investors and HNIs, in terms of shares and amount, are depicted in the table below.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 2,000 | Rs.122,000 |
| Retail (Max) | 1 | 2,000 | Rs.122,000 |
| S-HNI (Min) | 2 | 4,000 | Rs.244,000 |
| S-HNI (Max) | |||
| B-HNI (Min) | |||
| HNI (Min) |
| Share Holding Pre Issue | 88.60% |
| Share Holding Post Issue |
| Investor Category | Shares Offered | Maximum Allottees |
|---|---|---|
| Anchor Investor Shares Offered | |
|
| Market Maker Shares Offered | |
|
| Other Shares Offered | |
|
| QIB Shares Offered | Not more than 49.89% of the Net Issue |
|
| NII (HNI) Shares Offered | Not less than 15.07% of the Net Issue |
|
| bNII > ₹10L | |
|
| sNII < ₹10L | |
|
| Retail Shares Offered | Not less than 35.04% of the Net Issue |
|
| Employee Shares Offered | |
|
| Total Shares Offered | |
| Bid Date | |
| Shares Offered | |
| Anchor Portion Size (In Cr.) | |
| Anchor lock-in period end date for 50% shares (30 Days) | |
| Anchor lock-in period end date for remaining shares (90 Days) |
Incorporated in May 2005, Onyx Biotec Limited is recognized as a pharmaceutical company that provides sterile water for injections. Sterile Water for Injections is currently manufactured by the company, which also operates as a pharmaceutical contract manufacturer, offering a wide range of Dry Powder Injections and Dry Syrups for both Indian and overseas markets.
Two manufacturing units are operated by the company in Solan, Himachal Pradesh. Unit I has a daily production capacity of 638,889 units of Sterile Water for Injections, while Unit II produces 40,000 units of dry powder injections and 26,667 units of dry syrup per day in a single shift.
The clientele of the company includes Hetero Healthcare Limited, Mankind Pharma Limited, Sun Pharmaceutical Industries Limited, Aristo Pharmaceuticals Private Limited, Macleods Pharmaceuticals Limited, Mapra Laboratories Private Limited, Axa Parenterals Limited, FDC Limited, Zuventus Healthcare Limited, Akums Drugs and Pharmaceuticals Limited, Reliance Life Sciences Limited, among others.
| KPI | Values |
|---|---|
| ROE | |
| ROCE | |
| Debt/Equity | |
| RoNW | |
| P/BV | |
| PAT Margin (%) |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS (Rs) | 2.28 | 4.33 |
| P/E (x) | 26.81 | 14.1 |
The Net Proceeds from the Issue are proposed to be utilized by the Company towards the following objectives:
The existing manufacturing Unit I is proposed to be upgraded for the production of large volume parenterals intended for intravenous use.
A high-speed cartoning packaging line is proposed to be set up at the existing manufacturing Unit II for Dry Powder Injections.
The prepayment or repayment of all or a portion of certain loans availed by the Company is proposed.
Funds are proposed to be allocated for general corporate purposes.
Onyx Biotec Limited Bir Plassi Near Sainimajraropar, Nalagarh Road District Solan – 174101, Phone: +91 172 265 6384 Email: generalinfo@onyxbiotec.com Website: http://www.onyxbiotec.com/ |
Mas Services Limited Phone: (011) 2610 4142 Email: ipo@masserv.com Website: https://www.masserv.com/opt.asp |
Lamfindia specializes in offering innovative financial solutions, including stock broker services, mutual fund investments, and IPO guidance.